title: Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions.
abstract: Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic intervention that reduces the duration and severity of dengue symptoms and diminishes the likelihood of severe complications. To this end, there are active discovery efforts in industry and academia to develop interventions, with a focus on small molecule inhibitors of dengue virus replication that are suitable for therapy or chemoprophylaxis. Advancements in animal models of dengue virus infection together with the possibility of a dengue human infection model have further enhanced the platform for dengue drug discovery. Whilst drug discovery efforts gestate, there are ongoing clinical research designed to benefit today's patients, including trials of supportive care interventions, and descriptive studies that should improve the ability of clinicians to make an accurate diagnosis early in the illness course and to identify patients most at risk of progression to severe disease. This review provides a state of the art summary of dengue drug discovery, clinical trials, and supportive allied research and reflects discussions at the 2nd International Dengue Therapeutics Workshop held in Ho Chi Minh City, Vietnam, in December 2013.
authors.affiliation: Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom; Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.
authors.forename: James
authors.initials: J
authors.lastname: Whitehorn
authors.affiliation: Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; Department of Medicine, Imperial College, London, United Kingdom.
authors.forename: Sophie
authors.initials: S
authors.lastname: Yacoub
authors.affiliation: Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.
authors.forename: Katherine L
authors.initials: KL
authors.lastname: Anders
authors.affiliation: Armed Forces Research Institute of Medical Sciences U.S. Army Medical Component, Bangkok, Thailand.
authors.forename: Louis R
authors.initials: LR
authors.lastname: Macareo
authors.affiliation: National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of America.
authors.forename: M Cristina
authors.initials: MC
authors.lastname: Cassetti
authors.affiliation: Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.
authors.forename: Vinh Chau
authors.initials: VC
authors.lastname: Nguyen Van
authors.affiliation: Novartis Institute for Tropical Diseases, Singapore.
authors.forename: Pei-Yong
authors.initials: PY
authors.lastname: Shi
authors.affiliation: Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; Centre for Tropical Medicine, Oxford University, Oxford, United Kingdom.
authors.forename: Bridget
authors.initials: B
authors.lastname: Wills
authors.affiliation: Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; Centre for Tropical Medicine, Oxford University, Oxford, United Kingdom; Dept. of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia.
authors.forename: Cameron P
authors.initials: CP
authors.lastname: Simmons
mesh_terms: D000818:Animals; D000998:Antiviral Agents; D018890:Chemoprevention; D002986:Clinical Trials as Topic; D003715:Dengue / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008253:Macaca mulatta; D051379:Mice
chemical_list: D000998:Antiviral Agents